Home › Companies › DAY ONE BIOPHARMACEUTICALS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and DAY ONE BIOPHARMACEUTICALS INC.’s Form 8-K, filed June 3, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 2, 2025: 4 items on DAY ONE BIOPHARMACEUTICALS INC.’s Form 8-K, filed June 3, 2025: 4 passed (calculated).
Significant dissent: 1 director (21.3% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025
Explore DAY ONE BIOPHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are DAY ONE BIOPHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 3, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Natalie Holles | 81,975,302 | -- | -- | 1,357,027 | 6,470,934 | 98% | Passed (calculated) | — |
| Elect Director: Garry Nicholson, M.B.A. | 65,553,238 | -- | -- | 17,779,091 | 6,470,934 | 79% | Passed (calculated) | — |
| 2. The ratification of appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025. | 89,705,033 | 74,951 | 23,279 | -- | -- | 99.9% | Passed (calculated) | — |
| 3. The approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers. | 82,385,592 | 879,957 | 66,780 | -- | 6,470,934 | 99% | Passed (calculated) | — |
Source: DAY ONE BIOPHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 3, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
171 asset managers disclosed a vote on at least one DAY ONE BIOPHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Garry Nicholson
DAY ONE BIOPHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Garry Nicholson, M.B.A.”): 65,553,238 for, 17,779,091 withheld, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 54 asset managers below reported 22,866,484 for, 1,239,733 withheld, 104,089 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,729,592 | 0 | 0 | 0 | For |
| Vanguard | 5,825,813 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 2,334,142 | 0 | 0 | 0 | For |
| BlackRock | 2,169,498 | 0 | 0 | 0 | For |
| T. Rowe Price | 756,520 | 0 | 0 | 0 | For |
| Charles Schwab | 527,987 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 379,585 | Withhold |
| State Street | 335 | 0 | 0 | 154,122 | Withhold |
| Equitable | 85,995 | 0 | 0 | 62,790 | Mixed |
| TIAA | 137,846 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 110,000 | Withhold |
| Tema ETF Trust | 92,023 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,950 | 0 | 0 | 0 | For |
| WisdomTree | 0 | 0 | 0 | 77,906 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 76,829 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 67,343 | Withhold |
| SEI | 0 | 0 | 0 | 66,100 | Withhold |
| Exchange Place Advisors Trust | 0 | 0 | 49,857 | 0 | Abstain |
| MASTER INVESTMENT PORTFOLIO | 40,751 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 38,925 | Withhold |
| Northern Trust | 0 | 0 | 0 | 32,325 | Withhold |
| Global X | 0 | 0 | 0 | 32,210 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 28,227 | Withhold |
| JPMorgan | 24,836 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 21,188 | 0 | Abstain |
Showing the 25 largest of 54 asset managers. All 54 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Natalie Holles
DAY ONE BIOPHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Natalie Holles”): 81,975,302 for, 1,357,027 withheld, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 54 asset managers below reported 23,717,591 for, 473,269 withheld, 19,446 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,729,592 | 0 | 0 | 0 | For |
| Vanguard | 5,825,813 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 2,334,142 | 0 | 0 | 0 | For |
| BlackRock | 2,169,498 | 0 | 0 | 0 | For |
| T. Rowe Price | 756,520 | 0 | 0 | 0 | For |
| Charles Schwab | 527,987 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 379,585 | Withhold |
| State Street | 154,457 | 0 | 0 | 0 | For |
| Equitable | 85,995 | 0 | 0 | 62,790 | Mixed |
| TIAA | 137,846 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 110,000 | 0 | 0 | 0 | For |
| Tema ETF Trust | 92,023 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,950 | 0 | 0 | 0 | For |
| WisdomTree | 77,906 | 0 | 0 | 0 | For |
| Lincoln Financial | 73,329 | 0 | 0 | 3,500 | For |
| ALPS ETF Trust | 67,343 | 0 | 0 | 0 | For |
| SEI | 66,100 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 49,857 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 40,751 | 0 | 0 | 0 | For |
| ProShares | 38,925 | 0 | 0 | 0 | For |
| Northern Trust | 32,325 | 0 | 0 | 0 | For |
| Global X | 32,210 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 28,227 | 0 | 0 | 0 | For |
| JPMorgan | 24,836 | 0 | 0 | 0 | For |
| John Hancock | 19,851 | 0 | 1,337 | 0 | Mixed |
Showing the 25 largest of 54 asset managers. All 54 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Prior year: 99.2% for (May 23, 2024 meeting) ▼ 0.2 pts
Description as filed by funds: APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
DAY ONE BIOPHARMACEUTICALS INC.’s own tally for this item (“3. The approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers.”): 82,385,592 for, 879,957 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,729,592 | 0 | 0 | 0 | For |
| Vanguard | 5,825,813 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 2,334,142 | 0 | 0 | 0 | For |
| BlackRock | 2,169,498 | 0 | 0 | 0 | For |
| T. Rowe Price | 756,520 | 0 | 0 | 0 | For |
| Charles Schwab | 527,987 | 0 | 0 | 0 | For |
| Dimensional | 379,585 | 0 | 0 | 0 | For |
| State Street | 154,457 | 0 | 0 | 0 | For |
| Equitable | 148,785 | 0 | 0 | 0 | For |
| TIAA | 137,846 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 110,000 | 0 | 0 | 0 | For |
| Tema ETF Trust | 92,023 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,950 | 0 | 0 | 0 | For |
| WisdomTree | 77,906 | 0 | 0 | 0 | For |
| Lincoln Financial | 76,829 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 67,343 | 0 | 0 | 0 | For |
| SEI | 66,100 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 49,857 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 40,751 | 0 | 0 | 0 | For |
| ProShares | 38,925 | 0 | 0 | 0 | For |
| Northern Trust | 32,325 | 0 | 0 | 0 | For |
| Global X | 32,210 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 28,227 | 0 | 0 | 0 | For |
| JPMorgan | 24,836 | 0 | 0 | 0 | For |
| John Hancock | 21,188 | 0 | 0 | 0 | For |
Fund voting reports, all 54 managers: 24,189,860 for, 1,049 against, 19,397 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 12,119,185 | 0 | 0 | 0 | For |
| Atlas Venture Life Science Advisors, LLC | 6,430,257 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 4,913,327 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 3,935,683 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 3,348,466 | 0 | 0 | 0 | For |
| Estuary Capital Management LP | 3,318,406 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2,753,557 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 2,113,323 | 0 | 0 | 0 | For |
| BlackRock | 1,945,413 | 0 | 0 | 0 | For |
| Alyeska Investment Group, L.P. | 1,865,684 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 1,736,748 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,529,920 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,128,505 | 0 | 0 | 0 | For |
| State Street | 1,003,240 | 0 | 0 | 0 | For |
| EcoR1 Capital, LLC | 862,068 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 761,363 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 662,197 | 0 | 0 | 0 | For |
| Charles Schwab | 527,998 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 430,814 | 0 | 0 | 0 | For |
| Northern Trust | 377,567 | 0 | 0 | 0 | For |
| Stonepine Capital Management, LLC | 364,238 | 0 | 0 | 0 | For |
| UniSuper Management Pty Ltd | 350,000 | 0 | 0 | 0 | For |
| Citadel | 294,936 | 0 | 0 | 0 | For |
| AQR | 294,780 | 0 | 0 | 0 | For |
| NOMURA ASSET MANAGEMENT CO LTD | 249,625 | 0 | 0 | 0 | For |
Institutional-manager reports, all 135 managers: 55,918,462 for, 207,811 against, 106 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Prior year: 99.9% for (May 23, 2024 meeting) unchanged
Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.
DAY ONE BIOPHARMACEUTICALS INC.’s own tally for this item (“2. The ratification of appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.”): 89,705,033 for, 74,951 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 54 asset managers below reported 24,190,909 for, 19,397 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,729,592 | 0 | 0 | 0 | For |
| Vanguard | 5,825,813 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 2,334,142 | 0 | 0 | 0 | For |
| BlackRock | 2,169,498 | 0 | 0 | 0 | For |
| T. Rowe Price | 756,520 | 0 | 0 | 0 | For |
| Charles Schwab | 527,987 | 0 | 0 | 0 | For |
| Dimensional | 379,585 | 0 | 0 | 0 | For |
| State Street | 154,457 | 0 | 0 | 0 | For |
| Equitable | 148,785 | 0 | 0 | 0 | For |
| TIAA | 137,846 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 110,000 | 0 | 0 | 0 | For |
| Tema ETF Trust | 92,023 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,950 | 0 | 0 | 0 | For |
| WisdomTree | 77,906 | 0 | 0 | 0 | For |
| Lincoln Financial | 76,829 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 67,343 | 0 | 0 | 0 | For |
| SEI | 66,100 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 49,857 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 40,751 | 0 | 0 | 0 | For |
| ProShares | 38,925 | 0 | 0 | 0 | For |
| Northern Trust | 32,325 | 0 | 0 | 0 | For |
| Global X | 32,210 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 28,227 | 0 | 0 | 0 | For |
| JPMorgan | 24,836 | 0 | 0 | 0 | For |
| John Hancock | 21,188 | 0 | 0 | 0 | For |
Showing the 25 largest of 54 asset managers. All 54 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 87,389,859 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 12.28% |
| 2 | Vanguard | 6.67% |
| 3 | FRANKLIN STRATEGIC SERIES | 2.67% |
| 4 | BlackRock | 2.48% |
| 5 | T. Rowe Price | 0.87% |
| 6 | Charles Schwab | 0.60% |
| 7 | Dimensional | 0.43% |
| 8 | State Street | 0.18% |
| 9 | Equitable | 0.17% |
| 10 | TIAA | 0.16% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 13.87% |
| 2 | Atlas Venture Life Science Advisors, LLC | 7.36% |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 5.62% |
| 4 | FRANKLIN ADVISERS INC | 4.50% |
| 5 | PICTET ASSET MANAGEMENT SA | 3.83% |
| 6 | Estuary Capital Management LP | 3.80% |
| 7 | DEERFIELD MANAGEMENT COMPANY, L.P. | 3.15% |
| 8 | BRAIDWELL LP | 2.42% |
| 9 | BlackRock | 2.23% |
| 10 | Alyeska Investment Group, L.P. | 2.13% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| AI Day 1 LLC | 13,756,908 | 15.74% | Proxy statement (DEF 14A), proxy filed April 11, 2025 |
| FMR (Fidelity) | 13,700,448 | 15.68% | Form 13F, quarter ended March 31, 2025 |
| Fidelity | 12,887,467 | 14.75% | Proxy statement (DEF 14A), proxy filed April 11, 2025 |
| BlackRock | 6,757,929 | 7.73% | Form 13F, quarter ended March 31, 2025 |
| Entities affiliated with Atlas Venture | 6,430,257 | 7.36% | Proxy statement (DEF 14A), proxy filed April 11, 2025 |
| Vanguard Group | 5,943,243 | 6.80% | Form 13F, quarter ended March 31, 2025 |
| RA Capital Management, L.P. | 5,755,577 | 6.59% | Proxy statement (DEF 14A), proxy filed April 11, 2025 |
| Glazer Capital, LLC | 5,615,390 | 6.43% | Schedule 13G, filed March 19, 2026 |
| Franklin Templeton | 4,018,370 | 4.60% | Form 13F, quarter ended March 31, 2025 |
| Jeremy Bender, Ph.D., M.B.A. | 3,800,495 | 4.35% | Proxy statement (DEF 14A), proxy filed April 11, 2025 |
Percentages above are of 87,389,859 shares outstanding, as reported by DAY ONE BIOPHARMACEUTICALS INC. on its Form 10-Q dated May 1, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At DAY ONE BIOPHARMACEUTICALS INC.'s shareholder meeting held June 2, 2025, in the 2024-2025 proxy season, 171 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 906 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — FOR was 99% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: DAY ONE BIOPHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 3, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from DAY ONE BIOPHARMACEUTICALS INC.’s 10-Q dated May 1, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
DAY ONE BIOPHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page).
Proxy Votes Now, “DAY ONE BIOPHARMACEUTICALS INC. 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/day-one-biopharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.